Genentech’s Fenebrutinib Shows Breakthrough MS Results

Publisher: The Insight Partners

Genentech announced that fenebrutinib reached a major milestone in multiple sclerosis research. The company presented Phase III data at the Americas Committee for Treatment and Research in Multiple Sclerosis Forum. The study showed that Fenebrutinib slowed disability progression in primary progressive multiple sclerosis. Researchers confirmed that Fenebrutinib met its primary endpoint in the trial. The therapy demonstrated non-inferiority to Ocrevus, the only approved PPMS treatment.

In the FENtrepid trial, patients received daily oral Fenebrutinib. The drug reduced disability progression risk by 12 percent compared with Ocrevus at 24 weeks. Moreover, treatment curves were separated early in the study. Scientists also evaluated upper limb function during the trial. Fenebrutinib improved upper limb performance more than the standard therapy. Therefore, the findings highlight meaningful functional benefits for patients.

Professor Amit Bar-Or shared insights on the results. He leads the Center for Neuroinflammation and Neurotherapeutics at the University of Pennsylvania. He stated that Fenebrutinib showed consistent benefits as early as week 24. Furthermore, he emphasized the importance of preserving upper limb function. Patients rely on arm and hand mobility for daily independence.

The FENtrepid study forms part of the broader Fenebrutinib Phase III program. Researchers enrolled nearly 1,000 adults with PPMS. Participants received either daily oral Fenebrutinib or intravenous Ocrevus. The study continued for at least 120 weeks. Investigators measured disability using walking speed, limb coordination, and functional performance tests. These measurements provided a comprehensive view of disease progression.

Levi Garraway, Genentech’s Chief Medical Officer, described fenebrutinib as a potential breakthrough. He highlighted its meaningful benefit over the current standard of care. Additionally, he confirmed plans for regulatory submissions in 2026. The company expects further data from the FENhance 1 trial soon. Fenebrutinib already met the primary endpoint in the FENhance 2 relapsing MS study.

Experts believe Fenebrutinib could reshape MS treatment strategies. The therapy acts as an oral Bruton’s tyrosine kinase inhibitor. Importantly, Fenebrutinib crosses the blood-brain barrier to target central nervous system inflammation. This mechanism allows it to address both relapsing and progressive disease pathways. As a result, it may treat the underlying drivers of long-term disability. The development of novel multiple sclerosis therapies, increasing research and development efforts, and the rising prevalence of multiple sclerosis will continue to drive the use of multiple sclerosis drugs. The companies are focusing on various therapies, treatments, and drug development to treat multiple sclerosis.

Fenebrutinib differs from other BTK inhibitors in development. It binds reversibly and selectively to the BTK enzyme. Consequently, the design may reduce off-target effects. The drug targets B cells and microglia within the brain. By acting on these immune cells, Fenebrutinib addresses acute and chronic inflammation. This dual action may slow ongoing neurological damage.

Researchers closely monitored safety outcomes throughout the trial. Fenebrutinib showed a safety profile similar to Ocrevus. Common side effects included infections, nausea, and mild bleeding events. Some patients experienced temporary liver enzyme elevations. However, doctors managed these elevations effectively during treatment. Investigators reported fatalities in both groups but linked none to study drugs.

The Phase III program also includes two relapsing MS trials. FENhance 2 successfully reduced relapse rates in RMS patients. Meanwhile, researchers continue analyzing results from FENhance 1. Genentech plans to submit complete data packages to regulators. Approval could expand treatment options for both PPMS and RMS populations.

Multiple sclerosis affects millions worldwide. PPMS represents a particularly challenging form of the disease. Patients experience steady symptom worsening without clear relapses. Until now, Ocrevus served as the only approved PPMS therapy. Therefore, patients faced limited treatment choices.

Fenebrutinib now offers new hope for the MS community. The Phase III data demonstrate measurable clinical benefits. Moreover, the oral administration provides convenience compared with intravenous therapy. If approved, Fenebrutinib could redefine the PPMS treatment landscape. Physicians and patients now await regulatory review and final decisions.